Sodium perborate 1.5g powder for mouthwash sachets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Sodium perborate
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 30 studies.
Randomised trials: 1 · 1989–2026
Showing all 30 studies, sorted by most relevant.
Anles RD, Kottaigandhi GD, Sherwood IA, et al.
2026
Abstract Aim: This study compared the effectiveness, color stability, and patient satisfaction of Opalescence Endo and 30% hydrogen peroxide (HP) with sodium perborate in internal (walking) bleaching of discolored, root canal-treated maxillary anteriors. Materials and Methods: A total of 122 discolored teeth were randomly allocated into two groups: Group 1: Opalescence Endo ( n = 61) and Group 2: 30% hp with sodium perborate ( n = 61). Patients were recalled at 7-day intervals, with a maximum of three bleaching sessions. Bleaching efficacy was assessed subjectively using a 5-point Visual Analog Scale and objectively using CIELAB (∆E, Lightness Deviation Percentage, Lightness Recovery Percentage, L*). Statistical Analysis: Mann–Whitney U -test and Wilcoxon test were conducted for intergroup and intragroup comparisons, respectively. Results: Significant differences were observed in the L* value after treatment (Group 1: 81.66 and Group 2: 83.52), total days taken for bleaching (Group 1: 16.76 days and Group 2: 21.80 days), and the first-time color change noted by the patient (Group 1: 1.95 days and Group 2: 3 days), favoring the Opalescence Endo. For severely discolored teeth ( n = 15), a significant difference was observed in Lightness Recovery Percentage between the groups (Group 1: 72.97% and Group 2: 53.17%). Both groups showed high patient satisfaction and color stability over 12 months. Conclusion: Opalescence Endo demonstrated superior performance and faster bleaching compared to 30% HP with sodium perborate.
Abstract licence: CC BY-NC-ND
Alexander McKillop, William R Sanderson
Tetrahedron, 1995
Alexander McKillop, Duncan Kemp
Tetrahedron, 1989
Viengsai Phavongkham, S. Wattanasiriwech, T. Cheng, et al.
Construction and Building Materials, 2020
Jin-song Zhou, Xiongjian Du, Shile Zhou, et al.
Cellulose, 2023
Sheng Li, Jing Zou, Jiawen Li, et al.
Chemical Engineering Journal, 2024
Kaikai Gao, Yu Chen, H. Wang, et al.
BioEnergy Research, 2023
Aya Saad Wajeh, Hussein A. Jawad
Lasers in Dental Science, 2024
M. G. B. Albayrak, Sevinc Yanar, T. Korak, et al.
Journal of inorganic biochemistry, 2025
- Borates
- Neuroprotective Agents
- Proteomics
Halil Şenol
Bioresource technology, 2025
- Borates
- Methane
- Anaerobiosis
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q415507), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.